A visfatin promoter polymorphism is associated with low-grade inflammation and type 2 diabetes

被引:68
作者
Zhang, Yuan-Yuan
Gottardo, Lucia
Thompson, Ryan
Powers, Christine
Nolan, David
Duffy, Jill
Marescotti, Maria Cristina
Avogaro, Angelo
Doria, Alessandro
机构
[1] Joslin Diabet Ctr, Sect Genet & Epidemiol, Div Res, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA
[3] Univ Padua, Dept Clin & Expt Med, Padua, Italy
关键词
genetics; inflammation; type; 2; diabetes; visfatin/pre-B; cell colony-enhancing factor;
D O I
10.1038/oby.2006.247
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Visfatin (also known as pre-B cell colony-enhancing factor, or PBEF) is a pro-inflammator, adipokine expressed prey dominantly in visceral fat. We investigated whether polymorphisms at the visfatin/PBEF locus influence the risk of type 2 diabetes (T2D). Linkage disequilibrium analysis of 52 single nucleotide polymorphisms spanning the entire gene (34.7 kb) plus 20.5 kb of the upstream region and 25.5 kb of the downstream region revealed a single haplotype block that could be tagged by seven single nucleotide polymorphisms. These seven tags were typed in a group of T2D patients (n = 814) and a group of non-diabetic controls (n = 320) of white origin. A significant association was observed at -948C > A, with minor allele frequencies of 0.157 in T2D cases and 0.119 in non-diabetic controls (p = 0.021). In a non-diabetic population (n = 630), the same -948 allele that conferred increased risk of T2D was significantly associated with higher plasma levels of fibrinogen and C-reactive protein (p = 0.0022 and 0.0038, respectively). However, no significant associations were observed with BMI, waist circumference, serum glucose levels, or fasting insulin levels. Our findings suggest that the visfatin/PBEF gene may play a role in determining T2D susceptibility, possibly by modulating chronic, low-grade inflammatory responses.
引用
收藏
页码:2119 / 2126
页数:8
相关论文
共 25 条
[1]   The K121Q polymorphism of the ENPP1/PC-1 gene is associated with insulin resistance/atherogenic phenotypes, including earlier onset of type 2 diabetes and myocardial infarction [J].
Bacci, S ;
Ludovico, O ;
Prudente, S ;
Zhang, YY ;
Di Paola, R ;
Mangiacotti, D ;
Rauseo, A ;
Nolan, D ;
Duffy, J ;
Fini, G ;
Salvemini, L ;
Amico, C ;
Vigna, C ;
Pellegrini, F ;
Menzaghi, C ;
Doria, A ;
Trischitta, V .
DIABETES, 2005, 54 (10) :3021-3025
[2]   Haploview: analysis and visualization of LD and haplotype maps [J].
Barrett, JC ;
Fry, B ;
Maller, J ;
Daly, MJ .
BIOINFORMATICS, 2005, 21 (02) :263-265
[3]   Plasma visfatin concentrations and fat depot-specific mRNA expression in humans [J].
Berndt, J ;
Klöting, N ;
Kralisch, S ;
Kovacs, P ;
Fasshauer, M ;
Schön, MR ;
Stumvoll, M ;
Blüher, M .
DIABETES, 2005, 54 (10) :2911-2916
[4]   Genetic variation in the visfatin gene (PBEF1) and its relation to glucose metabolism and fat-depot-specific messenger ribonucleic acid expression in humans [J].
Boettcher, Yvonne ;
Teupser, Daniel ;
Enigk, Beate ;
Berndt, Janin ;
Kloeting, Nora ;
Schoen, Michael R. ;
Thiery, Joachim ;
Blueher, Matthias ;
Stumvoll, Michael ;
Kovacs, Peter .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (07) :2725-2731
[5]   Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus [J].
Chen, MP ;
Chung, FM ;
Chang, DM ;
Tsai, JCR ;
Huang, HF ;
Shin, SJ ;
Lee, YJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (01) :295-299
[6]   Macrophages in human visceral adipose tissue:: increased accumulation in obesity and a source of resistin and visfatin [J].
Curat, CA ;
Wegner, V ;
Sengenès, C ;
Miranville, A ;
Tonus, C ;
Busse, R ;
Bouloumié, A .
DIABETOLOGIA, 2006, 49 (04) :744-747
[7]   Inflammatory mediators and islet β-cell failure:: a link between type 1 and type 2 diabetes [J].
Donath, MY ;
Storling, J ;
Maedler, K ;
Mandrup-Poulsen, T .
JOURNAL OF MOLECULAR MEDICINE-JMM, 2003, 81 (08) :455-470
[8]   RETRACTED: Visfatin: A protein secreted by visceral fat that mimics the effects of insulin (Retracted article, see vol 318, pg 565, 2007) [J].
Fukuhara, A ;
Matsuda, M ;
Nishizawa, M ;
Segawa, K ;
Tanaka, M ;
Kishimoto, K ;
Matsuki, Y ;
Murakami, M ;
Ichisaka, T ;
Murakami, H ;
Watanabe, E ;
Takagi, T ;
Akiyoshi, M ;
Ohtsubo, T ;
Kihara, S ;
Yamashita, S ;
Makishima, M ;
Funahashi, T ;
Yamanaka, S ;
Hiramatsu, R ;
Matsuzawa, Y ;
Shimomura, I .
SCIENCE, 2005, 307 (5708) :426-430
[9]   Mechanisms of disease: Acute-phase proteins and other systemic responses to inflammation [J].
Gabay, C ;
Kushner, I .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (06) :448-454
[10]   The structure of haplotype blocks in the human genome [J].
Gabriel, SB ;
Schaffner, SF ;
Nguyen, H ;
Moore, JM ;
Roy, J ;
Blumenstiel, B ;
Higgins, J ;
DeFelice, M ;
Lochner, A ;
Faggart, M ;
Liu-Cordero, SN ;
Rotimi, C ;
Adeyemo, A ;
Cooper, R ;
Ward, R ;
Lander, ES ;
Daly, MJ ;
Altshuler, D .
SCIENCE, 2002, 296 (5576) :2225-2229